## KMB: Kimberly-Clark Corporation - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 3.2% below STRENGTH zone (4.0-10.0%); PEG 6.98 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($103.52)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Korea Investment CORP Sells 45,020 Shares of Kimberly-Clark Corporation $KMB**
- Source: MarketBeat | 20251130T112356 | Neutral | Relevance: 99%
- Korea Investment CORP significantly reduced its stake in Kimberly-Clark Corporation by selling 45,020 shares, though still holding a substantial position. This move comes as Kimberly-Clark announced a quarterly dividend and favorable quarterly earnings, beating analyst expectations. The stock currently holds a "Hold" rating from analysts with an average price target of $128.91, despite recent price target reductions by some firms.

**2. 4,313,640 Shares in Kimberly-Clark Corporation $KMB Acquired by Norges Bank**
- Source: MarketBeat | 20251201T112308 | Somewhat-Bullish | Relevance: 99%
- Norges Bank acquired a new position of 4,313,640 shares in Kimberly-Clark Corporation (KMB) during the second quarter, valued at approximately $556.1 million, representing about 1.30% ownership. Kimberly-Clark recently declared a quarterly dividend of $1.26 per share and reported Q3 earnings of $1.82 EPS, beating estimates. The stock currently has a consensus "Hold" rating from analysts with a target price around $128.91.

**3. Analysts Note Stronger Outlook as Kimberly-Clark (KMB) Deepens Its Consumer Health Footprint**
- Source: Finviz | 20251130T142500 | Bullish | Relevance: 99%
- Argus analyst John Stâ€Œaszak upgraded Kimberly-Clark Corporation (KMB) to a Buy rating with a $120 price target, citing better-than-expected third-quarter earnings and the planned acquisition of Kenvue. The acquisition is expected to deepen Kimberly-Clark's footprint in consumer health with resilient brands like Band-Aid and Tylenol, making KMB an appealing value pick for long-term investors despite recent stock lagging.

**4. Analysts Note Stronger Outlook as Kimberly-Clark (KMB) Deepens Its Consumer Health Footprint**
- Source: Insider Monkey | 20251130T142500 | Bullish | Relevance: 98%
-  Argus analyst John Staszak upgraded Kimberly-Clark Corporation (KMB) to a Buy rating with a $120 price target, citing better-than-expected Q3 earnings and plans to acquire Kenvue. The acquisition of Kenvue, which owns major consumer health brands, is expected to strengthen KMB's position in resilient product categories, making it an appealing value pick for long-term investors. Kimberly-Clark generates most of its revenue through direct sales to retailers and has a broad global footprint serving both consumer and professional markets.

**5. Trustmark Bank Trust Department Has $2.69 Million Stake in Kimberly-Clark Corporation $KMB**
- Source: MarketBeat | 20251201T132929 | Somewhat-Bullish | Relevance: 98%
- Trustmark Bank Trust Department reduced its stake in Kimberly-Clark Corporation by 12.8% in Q2, now holding 20,824 shares valued at $2.69 million. Kimberly-Clark reported strong Q3 earnings, beating EPS estimates and announcing a quarterly dividend of $1.26 per share. Institutional investors, including Vanguard Group Inc., have significant holdings, with analysts maintaining a "Hold" rating for the stock.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-01 | BNP Paribas Exa | $110 | $127 | -13% |
| 2025-11-13 | Argus Research | $120 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-01 | BNP Paribas Exa | main | Neutral |
| 2025-11-13 | Argus Research | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($1.08M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (+0.2%)
- Blackrock Inc.: 8.5% (+4.7%)
- State Street Corpora: 6.3% (+5.0%)
- Charles Schwab Inves: 3.5% (+1.2%)
- Geode Capital Manage: 2.5% (+0.0%)

### Key Risks

1. Valuation stretched: PEG 7.0x requires aggressive growth execution.
2. Long-term trend broken: trading 16.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +3.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.98 signals overvaluation risk, limited margin of safety. Forward P/E 14.2x stretched relative to 2% growth. Quality metrics strong (ROE 137%, ROA 11%). Analyst sentiment negative (1 target cuts vs 0 raises). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $34.2B |
| Beta | 0.26 |
| 52W Range | $99.22 - $150.45 |
| Short Interest | 5.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.98 |
| Forward P/E | 14.2 |
| Current P/E | 14.5 |
| YoY Growth | 2.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.0% to 3.2% (+3.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.8pp (needs >4.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. AM_20 at 4.3% shows strong absolute momentum above own 20MA. Below SMA200 (0.84x), long-term trend not supportive. MACD histogram positive (1.28), confirming momentum. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.17% (CS: 80) | Neutral |
| RSI_14 | 49.7 | Neutral |
| MACD Histogram | 1.28 | Bullish |
| vs SMA20 | 1.043x | Above |
| vs SMA50 | 0.950x | Below |
| vs SMA200 | 0.839x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $108.54
- **Stop Loss:** $103.52 (4.6% risk)
- **Target:** $113.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 239
- **Position Value:** $25,941.06
- **Portfolio %:** 25.94%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

### Earnings

**Next:** 2026-01-27 (Est: $1.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $1.82 | +3.9% |
| 2025Q2 | $1.66 | $1.63 | -1.5% |
| 2025Q1 | $1.89 | $1.93 | +2.0% |
| 2024Q4 | $1.51 | $1.50 | -0.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*